CTSL and PPP1CC |
cathepsin L |
protein phosphatase 1, catalytic subunit, gamma isozyme |
- Collagen formation
- Collagen degradation
- Degradation of the extracellular matrix
- Assembly of collagen fibrils and other multimeric structures
- Trafficking and processing of endosomal TLR
- Toll-Like Receptors Cascades
- MHC class II antigen presentation
- Endosomal/Vacuolar pathway
- Class I MHC mediated antigen processing & presentation
- Antigen processing-Cross presentation
- Adaptive Immune System
- Innate Immune System
|
- Loss of Function of TGFBR2 in Cancer
- Mitotic Prometaphase
- Metabolism of lipids and lipoproteins
- Separation of Sister Chromatids
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- Mitotic Anaphase
- TGFBR1 LBD Mutants in Cancer
- M Phase
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Lipid digestion, mobilization, and transport
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Resolution of Sister Chromatid Cohesion
- Mitotic Metaphase and Anaphase
- SMAD4 MH2 Domain Mutants in Cancer
|
|
- 9,10-Deepithio-9,10-Didehydroacanthifolicin
- Calyculin A
- (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID
- Motuporin
|
|
|
EGFR and EPS15 |
epidermal growth factor receptor |
epidermal growth factor receptor pathway substrate 15 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- Signaling by EGFR
- EGFR downregulation
- Signaling by EGFR in Cancer
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EGFR and STAM2 |
epidermal growth factor receptor |
signal transducing adaptor molecule (SH3 domain and ITAM motif) 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- Signaling by EGFR
- EGFR downregulation
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Signaling by EGFR in Cancer
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EGFR and NUMB |
epidermal growth factor receptor |
numb homolog (Drosophila) |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Hedgehog 'off' state
- Axon guidance
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- L1CAM interactions
- Recycling pathway of L1
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Hedgehog 'on' state
- Signaling by NOTCH1
- Signaling by Hedgehog
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Degradation of GLI1 by the proteasome
- Signaling by NOTCH1 in Cancer
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
EGFR and HGS |
epidermal growth factor receptor |
hepatocyte growth factor-regulated tyrosine kinase substrate |
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K/AKT activation
- PI-3K cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- Signaling by PDGF
- EGFR downregulation
- DAP12 interactions
- GAB1 signalosome
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- L1CAM interactions
- EGFR Transactivation by Gastrin
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signalling by NGF
- Signal transduction by L1
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Inhibition of Signaling by Overexpressed EGFR
- Signaling by FGFR
- SHC1 events in EGFR signaling
- Constitutive Signaling by EGFRvIII
|
- Signaling by EGFR
- EGFR downregulation
- Endosomal Sorting Complex Required For Transport (ESCRT)
- Signaling by EGFR in Cancer
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by EGFRvIII in Cancer
|
- Cetuximab
- Trastuzumab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Flavopiridol
- Vandetanib
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
- Afatinib
|
|
|
|
ERBB2 and HDAC6 |
erb-b2 receptor tyrosine kinase 2 |
histone deacetylase 6 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Axon guidance
- PIP3 activates AKT signaling
- GRB7 events in ERBB2 signaling
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- Innate Immune System
- Signaling by PDGF
- Downregulation of ERBB2:ERBB3 signaling
- Signalling by NGF
- DAP12 interactions
- GAB1 signalosome
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by ERBB4
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- HSF1 activation
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Organelle biogenesis and maintenance
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Assembly of the primary cilium
- Cellular response to heat stress
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Trastuzumab
- Lapatinib
- ado-trastuzumab emtansine
- Pertuzumab
- Afatinib
|
|
|
|
MTOR and TERT |
mechanistic target of rapamycin (serine/threonine kinase) |
telomerase reverse transcriptase |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- mTOR signalling
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- PKB-mediated events
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- S6K1-mediated signalling
- mTORC1-mediated signalling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by VEGF
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Costimulation by the CD28 family
- IRS-mediated signalling
- PIP3 activates AKT signaling
- mTOR signalling
- S6K1-mediated signalling
- mTORC1-mediated signalling
- IGF1R signaling cascade
- VEGFA-VEGFR2 Pathway
- HSF1-dependent transactivation
- IRS-related events triggered by IGF1R
- PI3K events in ERBB2 signaling
- Release of eIF4E
- VEGFR2 mediated vascular permeability
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Cellular response to heat stress
- Release of eIF4E
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PKB-mediated events
- PI3K Cascade
|
- Telomere Maintenance
- Chromosome Maintenance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- Extension of Telomeres
- Telomere Extension By Telomerase
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
|
|
|
|
|
FYN and PRKCZ |
FYN proto-oncogene, Src family tyrosine kinase |
protein kinase C, zeta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Signaling by EGFRvIII in Cancer
- Nef and signal transduction
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Regulation of KIT signaling
- PI3K/AKT activation
- PI-3K cascade
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Host Interactions of HIV factors
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- The role of Nef in HIV-1 replication and disease pathogenesis
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Signaling by VEGF
- Downstream signal transduction
- Sema3A PAK dependent Axon repulsion
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Nephrin interactions
- SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
- CRMPs in Sema3A signaling
- PI3K/AKT Signaling in Cancer
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- PIP3 activates AKT signaling
- HIV Infection
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Ephrin signaling
- EPH-ephrin mediated repulsion of cells
- PI3K events in ERBB2 signaling
- Regulation of signaling by CBL
- Downstream signaling of activated FGFR
- NCAM signaling for neurite out-growth
- Netrin-1 signaling
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- PECAM1 interactions
- CD28 dependent Vav1 pathway
- Signaling by FGFR
- Cell surface interactions at the vascular wall
- GPVI-mediated activation cascade
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
- Dasatinib
- 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
|
|
|
|
XRCC6 and SMAD7 |
X-ray repair complementing defective repair in Chinese hamster cells 6 |
SMAD family member 7 |
- Cytosolic sensors of pathogen-associated DNA
- HIV Infection
- Processing of DNA ends prior to end rejoining
- Integration of provirus
- Early Phase of HIV Life Cycle
- HIV Life Cycle
- Nonhomologous End-joining (NHEJ)
- STING mediated induction of host immune responses
- Double-Strand Break Repair
- IRF3-mediated induction of type I IFN
- 2-LTR circle formation
- Innate Immune System
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Signaling by BMP
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3A and PRKCZ |
glycogen synthase kinase 3 alpha |
protein kinase C, zeta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- XBP1(S) activates chaperone genes
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- IRE1alpha activates chaperones
- PI3K/AKT activation
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Unfolded Protein Response (UPR)
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
GSK3B and PRKCZ |
glycogen synthase kinase 3 beta |
protein kinase C, zeta |
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
|
NR4A1 and PPM1A |
nuclear receptor subfamily 4, group A, member 1 |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Nuclear Receptor transcription pathway
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Generic Transcription Pathway
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- IRS-mediated signalling
- mTOR signalling
- SMAD2/3 MH2 Domain Mutants in Cancer
- mTOR signalling
- TGFBR1 LBD Mutants in Cancer
- IGF1R signaling cascade
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- IRS-related events triggered by IGF1R
- Generic Transcription Pathway
- Energy dependent regulation of mTOR by LKB1-AMPK
- PKB-mediated events
- PI3K Cascade
- Signaling by Insulin receptor
- TGFBR2 MSI Frameshift Mutants in Cancer
- Insulin receptor signalling cascade
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Regulation of AMPK activity via LKB1
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- IRS-related events
- Loss of Function of TGFBR1 in Cancer
- IRS-mediated signalling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PKB-mediated events
- PI3K Cascade
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
NR4A1 and NCOR2 |
nuclear receptor subfamily 4, group A, member 1 |
nuclear receptor corepressor 2 |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- PIP3 activates AKT signaling
- Nuclear Receptor transcription pathway
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- Generic Transcription Pathway
- PI-3K cascade
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Innate Immune System
- Signaling by PDGF
- DAP12 interactions
- Signalling by NGF
- GAB1 signalosome
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by FGFR
- Signaling by ERBB2
- Signaling by EGFR
- AKT phosphorylates targets in the nucleus
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- HDACs deacetylate histones
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
IKBKB and TGFBR1 |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
transforming growth factor, beta receptor 1 |
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- RIP-mediated NFkB activation via ZBP1
- IRAK1 recruits IKK complex
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- FCERI mediated NF-kB activation
- Toll Like Receptor 5 (TLR5) Cascade
- NOD1/2 Signaling Pathway
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- IRAK1 recruits IKK complex
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- TCR signaling
- Signaling by Interleukins
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Fc epsilon receptor (FCERI) signaling
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Innate Immune System
- Signalling by NGF
- IKK complex recruitment mediated by RIP1
- Cytosolic sensors of pathogen-associated DNA
- p75 NTR receptor-mediated signalling
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Activation of NF-kappaB in B cells
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Loss of Function of TGFBR2 in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Mesalazine
- Sulfasalazine
- Auranofin
- Arsenic trioxide
|
|
|
|
IKBKB and PRKCZ |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
protein kinase C, zeta |
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- RIP-mediated NFkB activation via ZBP1
- IRAK1 recruits IKK complex
- Downstream signaling events of B Cell Receptor (BCR)
- Toll Like Receptor TLR1:TLR2 Cascade
- FCERI mediated NF-kB activation
- Toll Like Receptor 5 (TLR5) Cascade
- NOD1/2 Signaling Pathway
- MyD88 dependent cascade initiated on endosome
- Toll Like Receptor 9 (TLR9) Cascade
- IRAK1 recruits IKK complex
- TRIF-mediated TLR3/TLR4 signaling
- Toll Like Receptor 2 (TLR2) Cascade
- TCR signaling
- Signaling by Interleukins
- Toll Like Receptor 4 (TLR4) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Fc epsilon receptor (FCERI) signaling
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- Downstream TCR signaling
- p75NTR recruits signalling complexes
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- MyD88 cascade initiated on plasma membrane
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- Innate Immune System
- Signalling by NGF
- IKK complex recruitment mediated by RIP1
- Cytosolic sensors of pathogen-associated DNA
- p75 NTR receptor-mediated signalling
- Cytokine Signaling in Immune system
- MyD88-independent cascade
- Toll-Like Receptors Cascades
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Toll Like Receptor 10 (TLR10) Cascade
- Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
- Activation of NF-kappaB in B cells
- TRAF6 mediated NF-kB activation
- NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
- Mesalazine
- Sulfasalazine
- Auranofin
- Arsenic trioxide
|
|
|
|
IRS1 and PRKCZ |
insulin receptor substrate 1 |
protein kinase C, zeta |
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- PI3K/AKT activation
- PI-3K cascade
- SOS-mediated signalling
- PI3K Cascade
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Role of LAT2/NTAL/LAB on calcium mobilization
- Constitutive PI3K/AKT Signaling in Cancer
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Adaptive Immune System
- IRS-mediated signalling
- PIP3 activates AKT signaling
- IGF1R signaling cascade
- IRS-related events triggered by IGF1R
- IRS activation
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- Signaling by Insulin receptor
- Innate Immune System
- Signalling by NGF
- Insulin receptor signalling cascade
- SOS-mediated signalling
- Cytokine Signaling in Immune system
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- IRS-mediated signalling
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- PI3K Cascade
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
|
|
ITK and TGFBR1 |
IL2-inducible T-cell kinase |
transforming growth factor, beta receptor 1 |
- TCR signaling
- Generation of second messenger molecules
- Fc epsilon receptor (FCERI) signaling
- FCERI mediated Ca+2 mobilization
- Innate Immune System
- Adaptive Immune System
|
- Loss of Function of TGFBR2 in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
JAK1 and PRKCZ |
Janus kinase 1 |
protein kinase C, zeta |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- Interleukin-7 signaling
- SOS-mediated signalling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Downstream signal transduction
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- ISG15 antiviral mechanism
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- Regulation of IFNA signaling
- G-protein beta:gamma signalling
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Signaling by ERBB4
- Antiviral mechanism by IFN-stimulated genes
- Signaling by ERBB2
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Interferon alpha/beta signaling
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|
JAK2 and PPP1CC |
Janus kinase 2 |
protein phosphatase 1, catalytic subunit, gamma isozyme |
- Signaling by FGFR in disease
- Signaling by EGFRvIII in Cancer
- Interferon gamma signaling
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Interleukin receptor SHC signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Prolactin receptor signaling
- SHC-mediated signalling
- TRIF-mediated TLR3/TLR4 signaling
- ERK1 activation
- ERK1 activation
- GPCR downstream signaling
- Signaling by VEGF
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Signalling to RAS
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Axon guidance
- IRS-mediated signalling
- Interleukin-6 signaling
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- MyD88:Mal cascade initiated on plasma membrane
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- NCAM signaling for neurite out-growth
- RAF/MAP kinase cascade
- Signalling to p38 via RIT and RIN
- Innate Immune System
- Signaling by Insulin receptor
- Insulin receptor signalling cascade
- Interferon Signaling
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- IRS-related events
- SHC-related events
- RMTs methylate histone arginines
- Signaling by FGFR
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Nuclear signaling by ERBB4
- Toll Like Receptor 10 (TLR10) Cascade
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- Interleukin receptor SHC signaling
- GPVI-mediated activation cascade
- Signaling by GPCR
- FCERI mediated MAPK activation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- Signaling by PDGF
- DAP12 interactions
- G-protein beta:gamma signalling
- Chromatin organization
- GRB2 events in EGFR signaling
- SHC-related events triggered by IGF1R
- Factors involved in megakaryocyte development and platelet production
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- Chromatin modifying enzymes
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- Interleukin-3, 5 and GM-CSF signaling
- Growth hormone receptor signaling
- Signaling by Leptin
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- MyD88 cascade initiated on plasma membrane
- ERK activation
- G beta:gamma signalling through PI3Kgamma
- Downstream signaling of activated FGFR
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- ERK2 activation
- Regulation of IFNG signaling
|
- Loss of Function of TGFBR2 in Cancer
- Mitotic Prometaphase
- Metabolism of lipids and lipoproteins
- Separation of Sister Chromatids
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- Mitotic Anaphase
- TGFBR1 LBD Mutants in Cancer
- M Phase
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Lipid digestion, mobilization, and transport
- Cell Cycle, Mitotic
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Resolution of Sister Chromatid Cohesion
- Mitotic Metaphase and Anaphase
- SMAD4 MH2 Domain Mutants in Cancer
|
|
- 9,10-Deepithio-9,10-Didehydroacanthifolicin
- Calyculin A
- (2S,5R,8S,11R,12S,15S,18S,19S,E)-8-ISOBUTYL-18-((5S,6S)-6-METHOXY-3,5-DIMETHYL-7-PHENYLHEPTYL)-1,2,5,12,15,19-HEXAMETHYL-3,6,9,13,16,20,25-HEPTAOXO-1,4,7,10,14,17,21-HEPTAAZACYCLOPENTACOS-21-ENE-11,22-DICARBOXYLIC ACID
- Motuporin
|
|
|
LYN and PPP1R15A |
LYN proto-oncogene, Src family tyrosine kinase |
protein phosphatase 1, regulatory subunit 15A |
- Signaling by the B Cell Receptor (BCR)
- Platelet Adhesion to exposed collagen
- Axon guidance
- Costimulation by the CD28 family
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- EPHB-mediated forward signaling
- EPHA-mediated growth cone collapse
- Regulation of KIT signaling
- FCERI mediated NF-kB activation
- EPH-ephrin mediated repulsion of cells
- Regulation of signaling by CBL
- EPH-Ephrin signaling
- Fcgamma receptor (FCGR) dependent phagocytosis
- FCGR activation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- CD28 co-stimulation
- CTLA4 inhibitory signaling
- Cytokine Signaling in Immune system
- Role of LAT2/NTAL/LAB on calcium mobilization
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Signaling by Interleukins
- Fc epsilon receptor (FCERI) signaling
- GPVI-mediated activation cascade
- FCERI mediated Ca+2 mobilization
- Platelet activation, signaling and aggregation
- Interleukin-3, 5 and GM-CSF signaling
- Adaptive Immune System
- Growth hormone receptor signaling
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- Downregulation of TGF-beta receptor signaling
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
|
|
|
|